U.S. Markets closed

Humanigen, Inc. (HGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.84+0.54 (+5.81%)
At close: 4:00PM EST

9.80 -0.04 (-0.41%)
After hours: 7:02PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.30
Open9.22
Bid9.76 x 1000
Ask9.90 x 1200
Day's Range9.19 - 9.85
52 Week Range1.50 - 33.95
Volume420,142
Avg. Volume654,132
Market Cap507.906M
Beta (5Y Monthly)-0.88
PE Ratio (TTM)N/A
EPS (TTM)-2.00
Earnings DateNov 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.50
  • Is Humanigen, Inc. (HGEN) A Good Stock To Buy?
    Insider Monkey

    Is Humanigen, Inc. (HGEN) A Good Stock To Buy?

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

  • Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans
    Business Wire

    Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans

    Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the establishment of Humanigen Australia Proprietary Limited ("Humanigen Australia Pty Ltd"), through which Humanigen intends to assess potential partnering opportunities, facilitate clinical development programs, and conduct other corporate and business development activities in the Asia-Pacific region. The first of these was announced on November 3, with the execution of a licensing agreement for lenzilumab for South Korea and the Philippines.

  • Humanigen Reports Third Quarter and Nine Months Ended September 30, 2020 Financial Results
    Business Wire

    Humanigen Reports Third Quarter and Nine Months Ended September 30, 2020 Financial Results

    Humanigen, Inc., (HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab™, today reported financial results for the third quarter and nine months ended September 30, 2020, provided an overview of recent accomplishments and issued spending expense guidance for the remainder of 2020.